Abstract
Dr_Microbe / Getty Images
Curetis and BGI Group’s wholly-owned subsidiary MGI said they will partner to develop targeted next-generation sequencing (NGS) in vitro diagnostic assays for microbial infection. Under the collaboration, Curetis and MGI will develop an assay targeting a panel of pathogens and genetic antibiotic resistance markers.
The collaboration will combine Curetis’ Unyvero L4 Lysator with MGI’s SP100 Sample Preparation System and MGISeq NGS Sequencers, with the goal of creating an integrated workstation that will enable fully automated lysis, DNA extraction, NGS library preparation, and sequencing.
A Curetis wholly-owned subsidiary, Ares Genetics, will develop an app designed to enable interpretation of NGS data for pathogen identification and genetic antibiotic resistance markers. The app will be developed as a part of the data analysis software.
MGI plans to commercialize the assay in the Greater China market first, with Curetis potentially commercializing the diagnostic in other regions.